Preeclampsia can be a life-threatening complication of pregnancy, but a new blood test can help predict a woman’s risk for the condition while she is in her first trimester, the test’s maker said Wednesday. It’s the first test in the United States that can be used between 11 and 14 weeks gestation to determine the risk of preeclampsia before 34 weeks of pregnancy, Labcorp said in a news release announcing the launch of the test. “By giving healthcare providers another tool to assess preeclampsia risk in their pregnant patients with objective biomarkers, we’re helping to advance prenatal care and improve outcomes for mothers and their babies,” Labcorp’s Chief Medical and Scientific Officer Dr. Brian Caveney said in the news release. Roughly one in 25 U.S. pregnancies is affected by preeclampsia, which poses an even greater risk for Black women, who experience the condition at a 60% higher rate than white women do, the company noted. Still, some doctors wonder how much it will help. “It is currently unclear how useful the Labcorp test will be in accurately predicting risk for developing preeclampsia and whether it is appropriate for all pregnant patients,” Dr. Christopher Zahn, interim CEO at the American College of Obstetricians and Gynecologists (ACOG), told CNN. “Before a screening test can be successfully employed, there needs to be an evidence-based intervention to either prevent or reduce the impact of… read on > read on >







